Population
Coxsackievirus B3 3A protein (in silico molecular model and in vivo mutants)
Design
Preclinical
Authors
Loading...
Dimerization interfaces may guide antiviral design against coxsackievirus; leaves open in vivo efficacy and clinical translation.
Dimerization of the coxsackievirus B3 3A protein, driven by hydrophobic interactions and a salt bridge, is essential for viral RNA replication and inhibition of intracellular protein transport.
Wessels et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: